CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | Sherif Riad Director | Grant or award | +28,000 | 28,000 | ||
| 2026-11-06 | Sherif Riad Director | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2026-11-05 | Saroj Namrata Chief Business Officer | Sale 10b5-1 | −35,370 | $6.55 | $232K | 220,522 |
| 2026-10-08 | Anderman Todd Chief Legal Officer | Sale 10b5-1 | −11,984 | $7.29 | $87K | 140,484 |
| 2026-10-02 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −9,990 | $7.05 | $70K | 254,388 |
| 2026-10-02 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −10,869 | $7.05 | $77K | 307,457 |
| 2026-08-31 | Notman Donald Chief Operating Officer | Sale | −1,099 | $10.24 | $11K | 366,529 |
| 2026-08-25 | Dugel Pravin See Remarks | Gift 10b5-1 | −50,092 | 0 | ||
| 2026-08-25 | Dugel Pravin See Remarks | Gift 10b5-1 | +50,092 | 744,903 | ||
| 2026-08-24 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −3,035 | $10.77 | $33K | 264,378 |
| 2026-08-24 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,897 | $10.78 | $20K | 326,898 |
| 2026-08-24 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,296 | $10.78 | $36K | 318,326 |
| 2026-08-24 | Dugel Pravin See Remarks | Sale 10b5-1 | −21,649 | $10.77 | $233K | 2,525,429 |
| 2026-06-16 | Dugel Pravin See Remarks | Gift | −50,092 | 2,547,078 | ||
| 2026-06-16 | Dugel Pravin See Remarks | Gift | +50,092 | 50,092 | ||
| 2026-06-10 | Warden Charles M Director | Grant or award | +14,000 | 100,464 | ||
| 2026-06-10 | Warden Charles M Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-10 | Graves Adrienne L Director | Grant or award | +14,000 | 64,000 | ||
| 2026-06-10 | Graves Adrienne L Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-10 | Robins Jason Shand Chief Financial Officer | Grant or award | +15,441 | 68,097 |
Page 1 of 8 · 158 trades